Bharat Biotech to Cut Malaria Vaccine Price by 40% Under Gavi-UNICEF Agreement
Bharat Biotech will reduce the price of its malaria vaccine Mosqivac by about 40% starting early 2027 under an agreement with Gavi and UNICEF. The price will drop from $9.30 to $5.50 per dose, aiming to save $50 million for immunisation programs and protect an additional one million children. The vaccine, originally developed by GSK and now manufactured by Bharat Biotech, has been integrated into routine immunisation in 25 African countries, with demand exceeding initial forecasts.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 47/100.
Outlets measured: economictimes, news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 23 Oct, 08:34 am. Other outlets followed.